The Lancet Haematology · 2019 · 195 citations · 32 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyCancer ImmunotherapyCheckpoint Inhibitor TherapyCombination ImmunotherapyImmunotherapy SafetyPharmacodynamics Of ImmunotherapiesChronic Lymphocytic Leukemia TherapyNon-hodgkin Lymphoma TherapyNon-hodgkin Lymphoma TreatmentRelapsed Chronic Lymphocytic LeukemiaRelapsed Hodgkin LymphomaRelapsed Non-hodgkin LymphomaRituximab-based Therapy
32
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Lucio Crinò et al. · New England Journal of Medicine · 2015 · 8.6K citations · Full text
Pharmacy, Oncology, Pharmacotherapy +15
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
James Larkin, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2015 · 8.1K citations · Full text
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
Caroline Robert, Georgina V. Long, Benjamin Brady et al. · New England Journal of Medicine · 2014 · 5.4K citations · Full text
Medicine, Oncology, Pharmacotherapy +14
Michael Hallek, Bruce D. Cheson, Daniel Catovsky et al. · Blood · 2008 · 3.2K citations · Full text
Medicine, Hematology, Oncology +14